Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 2 (February)

1. Adjuvant chemotherapy in a pregnant woman with endodermal sinus tumor of the ovary.
   Obstet Gynecol, 109(2): 537-40. [Abstract] [Full-text]
2. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.
   Lancet Oncol, 8(2): 111-8. [Abstract] [Full-text]
3. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
   Oncogene, 26(5): 683-700. [Abstract] [Full-text]
4. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis.
   Cancer Sci, 98(3): 387-91. [Abstract] [Full-text]
5. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.
   Cancer Sci, 98(3): 380-6. [Abstract] [Full-text]
6. Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor.
   Biochem Pharmacol, 73(5): 675-81. [Abstract] [Full-text]
7. Genomic sweeping for hypermethylated genes.
   Bioinformatics, 23(3): 281-8. [Abstract] [Full-text]
8. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.
   Cancer Res, 67(3): 1317-25. [Abstract] [Full-text]
9. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.
   Br J Cancer, 96(3): 485-91. [Abstract] [Full-text]
10. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Oncogene, 26(6): 870-80. [Abstract] [Full-text]
11. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer.
    Expert Rev Proteomics, 4(1): 121-31. [Abstract] [Full-text]
12. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    J Clin Oncol, 25(5): 517-25. [Abstract] [Full-text]
13. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    J Clin Oncol, 25(5): 513-6. [Abstract] [Full-text]
14. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo.
    Mol Cancer, 6: 11. [Abstract] [Full-text]
15. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
    Cancer, 109(4): 692-702. [Abstract] [Full-text]
16. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Cancer, 109(4): 685-91. [Abstract] [Full-text]
17. Investigational agents against platinum-resistant ovarian cancer.
    Expert Opin Investig Drugs, 16(3): 325-36. [Abstract] [Full-text]
18. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
    Cancer Res, 67(4): 1859-66. [Abstract] [Full-text]
19. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.
    Cancer Res, 67(4): 1757-68. [Abstract] [Full-text]
20. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
    Cancer Res, 67(4): 1750-6. [Abstract] [Full-text]
21. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
    Cancer Res, 67(4): 1670-9. [Abstract] [Full-text]
22. Ovarian neuroendocrine carcinoma, non-small cell type, associated with serous carcinoma.
    Gynecol Oncol, 104(3): 747-52. [Abstract] [Full-text]
23. Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review.
    Gynecol Oncol, 104(3): 757-60. [Abstract] [Full-text]
24. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
    Gynecol Oncol, 104(3): 714-20. [Abstract] [Full-text]
25. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions.
    Gynecol Oncol, 104(3): 670-4. [Abstract] [Full-text]
26. Factors associated with return for routine annual screening in an ovarian cancer screening program.
    Gynecol Oncol, 104(3): 695-701. [Abstract] [Full-text]
27. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Gynecol Oncol, 104(3): 686-90. [Abstract] [Full-text]
28. Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients.
    Gynecol Oncol, 104(3): 680-5. [Abstract] [Full-text]
29. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.
    Gynecol Oncol, 104(3): 727-31. [Abstract] [Full-text]
30. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Gynecol Oncol, 104(3): 508-15. [Abstract] [Full-text]
31. Results of the national survey of borderline ovarian tumors in Spain.
    Gynecol Oncol, 104(3): 617-22. [Abstract] [Full-text]
32. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
    Gynecol Oncol, 104(3): 540-6. [Abstract] [Full-text]
33. A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
    Gynecol Oncol, 104(3): 607-11. [Abstract] [Full-text]
34. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.
    Gynecol Oncol, 104(3): 647-53. [Abstract] [Full-text]
35. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
    Gynecol Oncol, 104(3): 612-6. [Abstract] [Full-text]
36. Primary appendiceal cancer: gynecologic manifestations and treatment options.
    Gynecol Oncol, 104(3): 602-6. [Abstract] [Full-text]
37. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
    Gynecol Oncol, 104(3): 580-5. [Abstract] [Full-text]
38. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Gynecol Oncol, 104(3): 596-601. [Abstract] [Full-text]
39. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Gynecol Oncol, 104(3): 591-5. [Abstract] [Full-text]
40. Endometrioid-like yolk sac and Sertoli-Leydig cell tumors in a carrier of a Y heterochromatin insertion into 1qh region: a causal association?
    Cancer Genet Cytogenet, 173(2): 164-9. [Abstract] [Full-text]
41. Tumor vascular proteins as biomarkers in ovarian cancer.
    J Clin Oncol, 25(7): 852-61. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.